Quick Answer
Vaxart, Inc. reported Net Income Loss of $16.33 million for the year ending 2025.
- Vaxart, Inc. showed an increase of +124.4% in Net Income Loss from 2024 to 2025.
- This data is from Vaxart, Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2009 to 2025 (19 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 19 years of available data (2009 to 2025), Vaxart, Inc.'s Net Income Loss has grown by 187.2%.
- Historical annual values: Fiscal year 2025: $16.33 million | Fiscal year 2024: -$66.95 million | Fiscal year 2023: -$82.47 million | Fiscal year 2022: -$107.76 million | Fiscal year 2021: -$70.47 million | Fiscal year 2020: -$32.22 million | Fiscal year 2019: -$18.65 million | Fiscal year 2018: -$18.01 million | Fiscal year 2017: -$9.58 million | Fiscal year 2017: -$29.40 million | Fiscal year 2016: -$25.40 million | Fiscal year 2015: -$19.10 million | Fiscal year 2014: -$11.00 million | Fiscal year 2013: -$8.90 million | Fiscal year 2012: -$19.20 million | Fiscal year 2011: -$4.53 million | Fiscal year 2011: -$25.40 million | Fiscal year 2010: $878.0 thousand | Fiscal year 2009: -$18.73 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: